Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Rohto PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 3/4

Rohto PharmaceuticalLtd's CEO'su Yamada Kunio, Jun2009 tarihinde atandı, in görev süresi 15.33 yıldır. in toplam yıllık tazminatı ¥ 212.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 89.6% maaş ve 10.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.74% ine doğrudan sahiptir ve bu hisseler ¥ 14.09B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 5.3 yıldır.

Anahtar bilgiler

Yamada Kunio

İcra Kurulu Başkanı

JP¥212.0m

Toplam tazminat

CEO maaş yüzdesi	89.6%
CEO görev süresi	15.3yrs
CEO sahipliği	1.7%
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Oct 06

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Sep 22

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Aug 25

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

CEO Tazminat Analizi

Yamada Kunio'un ücretlendirmesi Rohto PharmaceuticalLtd'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	JP¥30b
Mar 31 2024	JP¥212m	JP¥190m	JP¥31b
Dec 31 2023	n/a	n/a	JP¥31b
Sep 30 2023	n/a	n/a	JP¥30b
Jun 30 2023	n/a	n/a	JP¥28b
Mar 31 2023	JP¥205m	JP¥183m	JP¥26b
Dec 31 2022	n/a	n/a	JP¥26b
Sep 30 2022	n/a	n/a	JP¥23b
Jun 30 2022	n/a	n/a	JP¥23b
Mar 31 2022	JP¥196m	JP¥178m	JP¥21b
Dec 31 2021	n/a	n/a	JP¥23b
Sep 30 2021	n/a	n/a	JP¥21b
Jun 30 2021	n/a	n/a	JP¥20b
Mar 31 2021	JP¥185m	JP¥176m	JP¥17b
Dec 31 2020	n/a	n/a	JP¥14b
Sep 30 2020	n/a	n/a	JP¥14b
Jun 30 2020	n/a	n/a	JP¥15b
Mar 31 2020	JP¥192m	JP¥179m	JP¥15b
Dec 31 2019	n/a	n/a	JP¥11b
Sep 30 2019	n/a	n/a	JP¥10b
Jun 30 2019	n/a	n/a	JP¥9b
Mar 31 2019	JP¥181m	JP¥173m	JP¥10b

Tazminat ve Piyasa: Yamada 'nin toplam tazminatı ($USD 1.43M ), JP pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.09M ).

Tazminat ve Kazançlar: Yamada 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Yamada Kunio (68 yo)

15.3yrs

Görev süresi

JP¥212,000,000

Tazminat

Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yamada Kunio	Chairman of the Board & CEO	15.3yrs	JP¥212.00m	1.74% ¥ 14.0b
Masashi Sugimoto	President	5.3yrs	Veri yok	0.0075% ¥ 59.9m
Saito Masaya	EVP, CFO & Director	2.6yrs	Veri yok	0.021% ¥ 165.6m
Shinichi Kunisaki	EVP, CTO & Director	2.6yrs	Veri yok	0.018% ¥ 144.5m
Hideto Kamimura	Senior Executive Officer and General Manager of Marketing Division	no data	Veri yok	0.0053% ¥ 42.3m
Yasunori Kawasaki	CHRO & Director	1.3yrs	Veri yok	Veri yok
Hidetoshi Segi	MD, Chief Strategy Officer & Director	2.6yrs	Veri yok	0.0039% ¥ 31.7m

2.6yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim: 4527 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yamada Kunio	Chairman of the Board & CEO	25.3yrs	JP¥212.00m	1.74% ¥ 14.0b
Masashi Sugimoto	President	5.3yrs	Veri yok	0.0075% ¥ 59.9m
Saito Masaya	EVP, CFO & Director	13.3yrs	Veri yok	0.021% ¥ 165.6m
Shinichi Kunisaki	EVP, CTO & Director	14.3yrs	Veri yok	0.018% ¥ 144.5m
Yasunori Kawasaki	CHRO & Director	1.3yrs	Veri yok	Veri yok
Hidetoshi Segi	MD, Chief Strategy Officer & Director	6.3yrs	Veri yok	0.0039% ¥ 31.7m
Kimura Masanori	Standing Corporate Auditor	8.3yrs	Veri yok	0.027% ¥ 215.0m
Akie Iriyama	Independent Outside Director	5.3yrs	Veri yok	Veri yok
Haruka Mera	Independent Outside Director	4.3yrs	Veri yok	Veri yok
Tatsuo Uemura	Independent Outside Director	2.3yrs	Veri yok	0.00044% ¥ 3.5m
Eriko Hayashi	Independent Outside director	2.3yrs	Veri yok	Veri yok
Maiko Katadae	Independent Outside Director	less than a year	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4527 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Rohto PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Less than half of directors are independent

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Less than half of directors are independent

Recent updates

Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price

Now 21% undervalued

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Upcoming dividend of JP¥16.00 per share

Now 20% undervalued

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Aug 09, 2022

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Consensus forecasts updated